Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease
Victor Chang Cardiac Research Institute, Lowy Packer Building, 405 Liverpool St., Darlinghurst NSW 2010, Australia
St. Vincent's Clinical School and School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington NSW 2052, Australia
Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, 08036 Barcelona, Spain
Senior Research Fellow, Sydney Medical School, University of Sydney, Sydney NSW 2006, Australia
School of Anatomy Physiology & Human Biology and The Harry Perkins Institute for Medical Research (CCTRM), Senior Research Fellow at the University of Western Australia, Crawley WA 6009, Australia
International Research Fellow, Victor Chang Cardiac Research Institute, Darlinghurst NSW 2010, Australia
Heart Centre for Children, The Children's Hospital at Westmead, Westmead NSW 2145, Australia
Sydney Medical School, University of Sydney, Sydney NSW 2006, Australia
Ear Science Institute Australia, Centre for Cell Therapy and Regenerative Medicine and School of Surgery, University of Western Australia, Nedlands WA 6009, Australia
Author to whom correspondence should be addressed.
Academic Editor: Jane Grant-Kels
Received: 22 December 2014 / Revised: 27 March 2015 / Accepted: 10 April 2015 / Published: 22 April 2015
Congenital heart disease places a significant burden on the individual, family and community despite significant advances in our understanding of aetiology and treatment. Early research in ischaemic heart disease has paved the way for stem cell technology and bioengineering, which promises to improve both structural and functional aspects of disease. Stem cell therapy has demonstrated significant improvements in cardiac function in adults with ischaemic heart disease. This finding, together with promising case studies in the paediatric setting, demonstrates the potential for this treatment in congenital heart disease. Furthermore, induced pluripotent stems cell technology, provides a unique opportunity to address aetiological, as well as therapeutic, aspects of disease.
This is an open access article distributed under the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Scifeed alert for new publications
Never miss any articles
matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
Define your Scifeed now
Share & Cite This Article
MDPI and ACS Style
Bosman, A.; Edel, M.J.; Blue, G.; Dilley, R.J.; Harvey, R.P.; Winlaw, D.S. Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease. J. Clin. Med. 2015, 4, 768-781.
Bosman A, Edel MJ, Blue G, Dilley RJ, Harvey RP, Winlaw DS. Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease. Journal of Clinical Medicine. 2015; 4(4):768-781.
Bosman, Alexis; Edel, Michael J.; Blue, Gillian; Dilley, Rodney J.; Harvey, Richard P.; Winlaw, David S. 2015. "Bioengineering and Stem Cell Technology in the Treatment of Congenital Heart Disease." J. Clin. Med. 4, no. 4: 768-781.
Show more citation formats
Show less citations formats
[Return to top]
For more information on the journal statistics, click here
Multiple requests from the same IP address are counted as one view.